bioRxiv: In-body screening finds FDA-approved SARS-CoV-2 replication inhibitors.

April 13, 2020 / / - The new coronavirus SARS-CoV-2, which began to appear at the end of 2019 and spread rapidly around the world, has infected more than 1.3 million people worldwide and killed more than 70,000 people.
there is no recognized treatment for SARS-Cov-2-related COVID-19 diseases, there is an urgent need to propose drug molecules that can enter the clinic quickly for treatment.
drugs for drug use is an effective strategy that bypasses the time-consuming phase of drug development.
photo source: Researchers from the University of Aix-Marseille recently published a study entitled "In vitro screening of a FDA approved chemical library reveals potential agents of SARS-CoV-2 replication" on the preprinted platform bioRxiv.
the study, researchers screened a Prestwick chemical library of 1,520 approved drugs.
researchers identified a total of 90 compounds.
researchers assess the stability and reliability of screening by identifying drugs already in clinical trials, such as chloroquine derivatives and protease inhibitors.
the drugs according to the chemical composition of the compounds and the known therapeutic effects, and then some of the compounds EC50 and CC50 were determined.
Researchers found several drugs, such as azithromycin, opioid parmesan, quinine, or omeprazole, with antiviral efficacy of 2 in general, and the study provided new information on in vitro molecules that inhibit SARS-CoV-2 replication, which may contribute to the short-term reuse of COVID-19 drugs.
() Reference: Frank Touret et al. In vitro screening of a FDA approved chemical library reveals potential resedors of SARS-CoV-2 replication. bioRxiv. 2020. doi: https://doi.org/10.1101/2020.04.03.023846.